HUGO-SHARE is a pilot project supported by the Health Data Hub and executed by GCS Hôpitaux Universitaires Grand Ouest (HUGO), an interregional public group of university hospitals in the greater western part of France. The project studies drug interactions that may cause adverse reactions, based on hospital prescriptions.

The project aims to enrich the National Data Bank of Rare Diseases (BNDMR) with data from the National Health Data System (SNDS) to identify and set up public health indicators.

The objective of this project is to establish the link between exposure to antibiotics and the incidence of resistant bacterial infection

A project piloted through the Health Data Hub and executed by Cochin Hospital (AP-HP) to identify and evaluate bone fractures in patients above 50 years of age and study their consequences: risk of new fractures, chronic pain, and risk of death.

The project aims to identify the impact of co-medications/comorbidities in breast cancer patients who are undergoing cancer treatment. The researchers will analyze  large-scale data from breast cancer patients in France since 2007 to observe the effect of pathologies (other than breast cancer) and their respective treatments may have on the evolution of the patients' breast cancer.

The aim of the SMPP is to study the impact of metabolic syndromes on the development of prostate cancer and adenocarcinoma.

The project which is led by researchers from the Saint Louis Hospital (AP-HP) aims to develop and train an AI algorithm to interpret ultrasound images of abdominal organs to detect main lesions.

The project aims to determine human papillomavirus (HPV) status on epidermal cancers of the upper airway and digestive tracts and predict response to therapies.

Develop a tool to automatically calculate the reporting rate of adverse events.

The DeepSarc project aims to identify the most suitable treatment for each sarcoma patient profile, thus favoring their chances of survival. In the long term, the results of this study conducted on "real world data" (as opposed to data collected in clinical trials) will make it possible to improve the treatment of sarcomas in patients that do not respond to standard treatments (approximately 50% of patients in France)